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Introduction
Duodenoscopes used to perform endoscopic retrograde cho-
langiopancreatography (ERCP) have structural features that
make their successful disinfection more challenging compared
with the standard endoscopes that are used for upper gastroin-
testinal endoscopy and colonoscopy. Specifically, the elevator
mechanism of a duodenoscope is accompanied by small spaces
that are difficult to access with manual cleaning tools, which
are therefore susceptible to the accumulation of debris and
bacteria that can potentially transmit infection between pa-
tients.
It is recommended that all endoscopes, including duodeno-
scopes, undergo standardized steps of manual cleansing and
disinfection after each use. Failure to reprocess endoscopes ac-
cording to these detailed protocols has been recognized for 4
decades to create infection risk [1–12]. Recently, however, a
general dogma that endoscopic transmission of infection can
be prevented by strict adherence to disinfection protocols has
been challenged in the case of duodenoscopes [9–12]. An out-
break of ERCP- transmitted infection could not be attributed to
a breakdown in cleaning and disinfection processes [13]. The
conclusion that ERCP scopes could transmit infection despite
the performance of cleaning and disinfection according to re-
commended protocols for high-level disinfection (HLD) led to
reassessment and revision of HLD recommendations by the
Food and Drug Administration (FDA) [14–16] and the Centers
for Disease Control and Prevention (CDC) [17].
The urgency to reduce duodenoscope-transmitted infection
is magnified because some of the reported outbreaks have
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ABSTRACT
Background and study aim Duodenoscopes have been
the source of serious infection, despite correct perform-
ance of high-level disinfection (HLD). This study aimed to
observe the impact of performing HLD twice on the rate of
positive cultures from duodenoscope elevators.
Methods We performed double HLD (DHLD; i. e. complete
manual cleaning followed by automated reprocessing, with
the entire process repeated) and then randomly cultured
the elevators of our duodenoscopes on about 30% of occa-
sions.
Results DHLD was associated with positive elevator cul-
tures for any microorganism in 9.4% of cases, with a 0.8%
rate of known pathogens (627 cultures) between May
2015 and February 2016. After February 2016, and in asso-
ciation with changing the precleaning fluid, as well as use of
a new FDA-recommended cleaning brush, the rate of posi-
tive cultures for any microorganism after DHLD was 4.8%
and 0.2% for known pathogens (420 cultures). In a third
phase, characterized by a change in personnel performing
DHLD and retirement of a duodenoscope with a high rate
of positive cultures, the rate of positive cultures for any mi-
croorganism was 4.9% (783 cultures) and the rate of posi-
tive culture for known pathogens was 0.3%. To our knowl-
edge, no duodenoscope transmission of infection occurred
during the study interval.
Conclusions DHLD resulted in a low rate of positive cul-
tures for known pathogens and for organisms of low patho-
genic potential, but did not eliminate these, from duodeno-
scope elevators. Additional improvements in HLD protocols
and/or duodenoscope design are needed.
Original article
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been with carbapenem-resistant Enterobacteriaceae (CRE) [18,
19], also called carbapenemase-producing Enterobacteriaceae
(CPE). CREs are gram-negative bacteria including Klebsiella
species, Enterobacter species, and Escherichia coli that hydro-
lyze carbapenem antibiotics. CRE infections are associated
with mortality rates approaching 50%, particularly in immuno-
compromised patients [18, 19].
The FDA has recommended that endoscopy centers perform
HLD on duodenoscopes, and that those centers with the cap-
ability consider 1 of 4 supplemental measures to reduce infec-
tion risk including: microbiological culturing, ethylene oxide
(EtO) sterilization, use of a liquid chemical sterilant processing
system, or repeat high-level disinfection [20]. In the most re-
cent version of the Multisociety reprocessing guideline [21], it
was recommended that units “should review and consider the
feasibility and appropriateness for their practice of 1 or more”
of these same 4 modalities. Whether any of the supplemental
measures recommended by the FDA, or which of them, can
eliminate the risk of ERCP-transmitted infection or eliminate
positive cultures from duodenoscopes remains uncertain.
Endoscopy centers that have experienced ERCP-transmitted
outbreaks of CRE infection have responded in some instances
by dramatic changes in their management of duodenoscopes,
even prior to the FDA recommendations. These steps have in-
cluded EtO sterilization of duodenoscopes [22] and universal
culturing of duodenoscopes with sequestering of scopes pend-
ing culture results [23].
Our center performs approximately 3000 ERCPs per year. Be-
cause of an awareness of duodenoscope-transmitted CRE infec-
tions without any apparent breakdown in reprocessing [13], we
met to develop an approach to preventing transmission of in-
fection by ERCP in our center.
The first issue was the small size of our duodenoscope fleet,
which was 16 instruments. It appeared that any measure we
would take would require more instruments, and therefore we
purchased 40 reprocessed duodenoscopes (8 TJF-Q180V and
32 TJF-160VF; Olympus America Inc., Center Valley, Pennsylva-
nia, USA). Refurbishment of these previously used instruments
included inspection of the channels and replacement of any da-
maged channels.
EtO is available to us, but our capacity to perform EtO steri-
lization was not sufficient to handle the volume of ERCP proce-
dures performed in our center. Furthermore, EtO creates envir-
onmental risks as well as health risks for EtO workers [22, 24,
25] and there is uncertainty as to whether EtO damages endo-
scopes [22, 24]. The alternative of universal culture and seques-
tering of duodenoscopes [23] was also not feasible because our
clinical laboratory lacked the capacity to culture the volume of
duodenoscopes used in our center, and we could not identify
any local environmental laboratory capable of providing univer-
sal culturing at a reasonable cost.
We decided to follow another of the recommended courses
of action, namely complete doubling of all steps of both manual
cleaning and HLD, which we refer to as double HLD (DHLD).
DHLD was 1 of the 4 supplemental measures suggested by the
FDA, and we devoted resources to culture a feasible fraction of
the duodenoscopes after DHLD to monitor the process. Here
we report the incidence of positive elevator cultures after
DHLD, and the incidence of CRE transmission of infection dur-
ing application of this program.
Methods
Study period
Before initiating the protocol in May 2015, the entire fleet of 56
duodenoscopes (TJF-160VF, n =35; TJF-Q180V, n =8; JF-140, n =
6; JF-130, n=3; TJF-160F, n=2; TJF-140F, n=1; PJF160, n =1) un-
derwent single-time EtO. The DHLD protocol started in May
2015 and continues through to the present time, with the cul-
ture results reported here extending until May 2017.
All culture results were recorded prospectively along with
the identity of the duodenoscope and the procedure and cul-
ture date. Permission to report the results was granted by our
Institutional Review Board.
Double-reprocessing HLD protocol
Each round of HLD in the DHLD protocol was performed accord-
ing to the recommendations of the manufacturer, the FDA
[14–16], the CDC [17], and the American Society of Gastro-
intestinal Endoscopy (ASGE) [26, 27] that were available or
became available during the study period. As per the already
established protocol in our unit, all HLD was performed by dedi-
cated staff whose only work in the unit is cleaning and disinfec-
tion.
Manual cleaning
Following each ERCP, the duodenoscope external surface was
wiped and the channels were irrigated using an enzymatic solu-
tion. From May 2015 through to February 2016, the Compli-
ance EndoKit (Endochoice, Alpharetta, Georgia, USA) was used
for this step. In March 2016, after reviewing results, we chan-
ged to the Intercept system (Medivators Inc., Minneapolis, Min-
nesota, USA) for precleaning. In September 2016, the foaming
agent in the Intercept system became unavailable and the
foaming step was left out of the Intercept precleaning process.
From December 2016, Medivators supplied us with a modified
foaming agent and we continued the use of this agent through
to the end of the study.
After precleaning, the duodenoscope was transferred to the
endoscope reprocessing area to complete the manual cleaning
process. The duodenoscope was immersed in enzymatic deter-
gent solution (Revital-Ox; Steris Corporation, Mentor, Ohio,
USA until March 2016; the Intercept system thereafter) and
thoroughly cleaned using a single-use, manufacturer-recom-
mended brush to remove all visible debris. All areas of the duo-
denoscope were cleaned, including the elevator, elevator re-
cess, elevator locking mechanism, suction port, air/water port,
and instrument-channel port. Manual cleaning was continued
until no debris was visible on the duodenoscope. The instru-
ment channels and suction port were also irrigated with the de-
tergent solution. The channels were manually cleaned using
brushes. Special brushes manufactured by Olympus for clean-
ing the elevator of the 180 series and subsequently the 160 se-
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ries duodenoscopes were used as they became available
(▶Fig.1).
Automated reprocessing
Following manual cleaning, the duodenoscope was placed in an
automated endoscope reprocessor (Medivators Inc.) for a total
cycle time of approximately 30 minutes (depending on the
amount of time taken to heat the water to the appropriate tem-
perature), using a high-level disinfectant (Rapicide PA Parts A
and B; Medivators Inc.), then rinsed with filtered sterile water.
The entire process of manual cleaning and reprocessing was
then repeated to complete the DHLD protocol. All duodeno-
scopes were dried thoroughly and hung in the storage closet
exposed to room air, except for those selected to undergo cul-
turing. The storage closets did not employ forced air drying.
Any duodenoscope not used for 7 days underwent repeat HLD
and was then rehung for storage.
Monitoring and culture management
The infection control department tracked all CRE infections and
notified the ERCP physician by electronic alert of any patient
undergoing ERCP with a known CRE infection. Any duodeno-
scope used in a patient with a history of CRE infection under-
went HLD and then EtO sterilization. In addition, the medical
records of any patient with CRE-positive cultures in the hospital
were examined to determine if an ERCP had been performed
previously.
Duodenoscopes were not cultured immediately after DHLD.
Instead instruments were hung in a storage closet between
completion of DHLD and culturing. All duodenoscope cultures
were performed by 1 of 5 trained staff in accordance with CDC
and FDA guidelines [14, 17], with the addition that the channel
cultures included material obtained from brushing the chan-
nels. For the first 3 months of the DHLD protocol, the most fre-
quently used duodenoscopes in the prior week were randomly
selected to undergo culturing of both the working channels and
the elevator mechanism. However, after all of the 120 initial
cultures from the working channels were found to be negative,
the culture process was confined to the elevator mechanism.
We initially cultured 10, and then increased to 20, of the
most frequently used duodenoscopes per week (10 scopes
were cultured every Monday and 10 every Wednesday). This
rate of culturing constituted about 30% of all duodenoscopes
when 20 instruments per week were cultured. During this time
period, all duodenoscopes in our fleet were cultured at least
once. All cultured duodenoscopes underwent a third round of
HLD because of the potential risk of endoscope contamination
during the culturing process, as per FDA guidelines.
Each swab sample was placed in 10mL of tryptic soy broth
and vortexed for 5 seconds to dislodge any particulate matter.
The swabs were then incubated in tryptic soy broth at 37.0 °C.
The broth was checked for turbidity at 24 and 48 hours. If tur-
bidity of the broth was noted, 10μL was subcultured onto tryp-
tic soy agar (TSA) with 5% sheep blood, MacConkey and CNA
agars (Remel, Lenexa, Kansas, USA), and a Gram stain of the
broth was performed.
Each cultured duodenoscope was sequestered pending cul-
ture results. Duodenoscopes with negative culture results
were released for use after sequestration for 48 hours. Duode-
noscopes with positive culture results for any microorganism
remained sequestered and underwent repeat culturing fol-
lowed by another HLD cycle. Those with negative cultures
were then released for use, while those with a second consecu-
tive positive culture result for any microorganism underwent
EtO sterilization. Duodenoscopes which underwent EtO sterili-
zation were released for use without repeat culturing. A flow
diagram of the DHLD protocol is shown in ▶Fig. 2.
▶ Fig. 1 The Olympus brushes designed for cleaning the elevators
of duodenoscopes: a the single-use MAJ-1888 for use on 180 se-
ries duodenoscopes, made available in May 2015; b the reusable
MAJ-1534 for use on 160 series duodenoscopes, made available in
March 2016.
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Study endpoints
The primary outcome measures were: (i) the incidence of posi-
tive cultures (microorganisms with both high and low patho-
genic potential) and (ii) the incidence of duodenoscope-asso-
ciated infection at our institution following implementation of
the DHLD protocol. Microorganisms with high pathogenic po-
tential were defined as those known to cause infections of any
significance requiring antimicrobial therapy in humans [17],
and are also referred to here as “known pathogens.” Microor-
ganisms with low pathogenic potential were defined as those
not known to cause significant infections in humans or known
commensal organisms.
Statistical analysis
Phase 1
For the initial testing of the DHLD protocol, we performed a
sample size calculation using nQuery (Statistical Solutions Ltd,
Boston, Massachusetts, USA) with an alpha of 0.05 for a 2-sided
test and a power of 90% for detecting a 75% reduction in the
rate of positive cultures with known pathogenic organisms fol-
lowing DHLD, compared with the expected rate of 2% of patho-
genic cultures based on an initial report of cultures after single-
reprocessing HLD [23]. This resulted in a target sample size of
592 duodenoscope cultures. Duodenoscope culture results
were compiled and then summarized as frequencies and pro-
portions using Microsoft Excel (Microsoft Corporation, Red-
mond, Washington, USA).
Phase 2
After the sample size of cultures for assessing the DHLD proto-
col was reached, we elected to test the effect of changing the
precleaning solution to the Intercept System. Using a baseline
incidence of 9.4% for any microorganism (see below) deter-
mined for the DHLD protocol, we calculated using PASS13
(NCSS, Kaysville, Utah, USA) that a sample size of 263 cultures
was needed to determine whether the Intercept system was
associated with a 50% reduction in the overall culture positivity
rate.
Phase 3
In August 2016, we identified that 2 employees involved in the
DHLD process may have skipped part or all of the second man-
ual cleaning steps for some of the scopes cleaned during phase
2.When confronted both employees admitted to at least some
violations of the protocol and were immediately dismissed from
hospital employment. We transferred new personnel in and be-
gan their training in DHLD. This event is referred to as the be-
ginning of phase 3.
We instituted increased unannounced spot audits of the
DHLD process to ensure compliance with all steps of the DHLD
protocol. Approximately 4 weeks into phase 3, we stopped
using the foaming agent in the Intercept precleaning process
because of lack of availability and returned to the previously
used standard precleaning measures. An altered foaming agent
that is not commercially available was supplied to us 12 weeks
later by Medivators; we began using this immediately and con-
tinued to use it through to the end of the study. We continued
phase 3 until the sample size for the cultures exceeded the tar-
get size (n≥263).
A chi-squared test was used to compare the occurrence of a
positive culture for any microorganism between the scope se-
ries (e. g. 180 series vs. 160 series). Fisher’s exact test was
used to compare the occurrence of a probable pathogen be-
tween the scope series.
Results
From May 2015 to February 2016, 627 cultures were obtained
from 56 duodenoscopes reprocessed by DHLD. All duodeno-
scopes were sampled at least once (the median times each duo-
denoscope was cultured was 11 [range 1–18]).
From 15 May 2015 to 19 August 2015, none of the 120 non-
elevator channel cultures were positive. From 15 May 2015 to
17 February 2016, 59 of 627 elevator cultures (9.4%) were po-
sitive (▶Table 1). Known pathogenic microorganisms were
found in 5 cultures (0.8%) from 5 separate cultures (1 Candida
Endoscope manually cleaned and high-level 
disinfection (HLD; Medivator) performed × 2  
Endoscope cultured
Endoscope manually cleaned again and HLD × 1
Endoscope sequestered
Endoscope 
recultured
Endoscope manually 
cleaned again and HLD × 1
Endoscope sequestered
Culture results
Endoscope sent for ethylene 
oxide sterilization
Approved for 
patient use
Culture 
results
Positive
culture 
Positive culture 
No 
growth
No 
growth
Approved for 
patient use
▶ Fig. 2 Flowchart showing the cleaning and culturing processes
for duodenoscopes and the management on the basis of culture
results. About 30% of the duodenoscopes used were cultured.
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glabrata, 1 Zygomycete and 3 Enterococcus spp.) (▶Table 2).
The remaining positive cultures consisted of microorganisms
of low pathogenic potential and included Micrococcus spp. in
40, coagulase-negative Staphylococcus spp. in 10, and Bacillus
spp. in 4 (▶Table 2).
6 duodenoscopes had 2 consecutive positive cultures (with
any microorganism) and by protocol underwent EtO steriliza-
tion. A single 160 series duodenoscope did not have 2 consecu-
tive positive cultures but had an overall 25% rate of positive cul-
tures. This same instrument accounted for 2 of the initial 6 po-
sitive cultures for known pathogens (including the 1 culture of a
known pathogen in the second phase of the study– see below).
This duodenoscope underwent EtO followed by culture after
every use. Culture after every use quickly identified that the
duodenoscope could not be effectively disinfected by DHLD
and it was removed from service near the end of phase 2 (see
below).
In February 2016, after a final review of the culture results
noted above, we changed the precleaning solution to the Inter-
cept system (Medivators Inc.), initiating the period we referred
to as phase 2. We continued the culture process throughout
phase 2, but allowed a 2-week run-in period of performing
DHLD with the Intercept system before measuring the culture
rate associated with the Intercept system. Between March and
August 2016, 420 duodenoscope elevator cultures were ob-
tained, with 20 positive cultures (4.8%) for any microorganism
and 1 (0.2%) for a known pathogen. The known pathogen was
again an Enterococcus species, and the organisms of low pa-
thogenic potential were again predominantly coagulase-nega-
▶Table 1 Comparison of high-level disinfection protocols and culture results between 2 studies.
Ross et al.
[23]
Current study
Phase 1 Phase 2 Phase 3
Total number of duodenoscopes cultured, n 1524 627 420 783
Overall culture positive rate, n (%) [95%CI]  200 (13.1)  59 (9.4) [7.2–12.0]  20 (4.8) [2.9–7.3]  38 (4.9) [3.5 –6.6]
Pathogenic culture positive rate, n (%) [95%CI]   29 (1.9)   5 (0.8) [0.3–1.9]   1 (0.2) [0.0–1.3]   2 (0.3) [0.0 –0.9]
Non-pathogenic culture positive rate, n (%) [95%CI]  171 (11.1)  54 (8.6) [6.5–11.1]  19 (4.5) [2.8–7.0]  36 (4.6) [3.2 –6.3]
Number of sessions of manual cleaning    1   2   21   2
Number of sessions of automated reprocessing    1   2   2   2
Percentage of duodenoscopes cultured  100 ~30 ~30 ~30
CI, confidence interval.
1 Some sessions of the second round of manual cleaning were omitted.
▶Table 2 Summary of duodenoscope culture results in the 3 phases of the study.
Phase 1 Phase 2 Phase 3
Total cultures 627 420 783
Total positive cultures, n (%) [95%CI]  59 (9.4) [7.2–12.0]  20 (4.8) [2.9–7.3]  38 (4.9) [3.5–6.6]
Organisms of high pathogenic potential (“known pathogens”), n (%) [95%CI]
▪ Overall   5 (0.8) [0.3–1.9]   1 (0.2) [0.0–1.3]   2 (0.3) [0.0–0.9]
▪ Enterococcus   3 (0.5) [0.1–1.4]   1 (0.2) [0.0–1.3]
▪ Candida species   1 (0.16) [0.0–0.9]   0 (0) [0.0 –0.9]   2 (0.3) [0.0–0.9]
▪ Zygomycete   1 (0.16) [0.0–0.9]   0 (0) [0.0 –0.9]   0 (0) [0.0–0.5]
Organisms of low pathogenic potential, n (%) [95%CI]
▪ Overall  54 (8.6) [6.5–11.1]  19 (4.5) [2.8–7.0]  36 (4.6) [3.2–6.3]
▪ Micrococcus  40 (6.4) [4.6–8.6]   6 (1.4) [0.5–3.1]   7 (0.9) [0.4–1.8]
▪ Coagulase-negative Staphylococcus  10 (1.6) [0.8–2.9]   5 (1.2) [0.4–2.8]  24 (3.1) [2.0–4.5]
▪ Bacillus   4 (0.6) [0.2–1.6]   6 (1.4) [0.5–3.1]   4 (0.5) [0.1–1.3]
▪ Corynebacterium   0 (0) [0.0–0.6]   2 (0.5) [0.1–1.7]   1 ( < 0.1) [0.0–0.7]
CI, confidence interval.
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tive Staphylococcus spp., Bacillus spp., and Micrococcus spp.
(▶Table 2).
Phase 3 of the culture process (August 2016 to May 2017)
was characterized by an abrupt change in personnel perform-
ing the DHLD protocol and also initially, beginning about 4
weeks into phase 3, by a lack of availability of the foaming
agent in the Intercept precleaning protocol. During phase 3,
the rate of positive cultures for any microorganism was 4.9%
and the rate for known pathogens was 0.3% (783 cultures).
During phase 3, there appeared to be a spike in the positive cul-
ture rate during the first 4 weeks (during which time the 2 new
personnel were being trained) with an overall rate of positive
cultures for any microorganism of 12.7% and for pathogens of
1.3% (79 cultures). In the final 704 cultures of phase 3, the rate
of positive cultures for any microorganism was 3.9% and the
rate of culture for known pathogens was 0.14%. During phases
2 and 3 combined, 7 more duodenoscopes had 2 consecutive
positive cultures for any micoorganism and underwent EtO
sterilization.
▶Table 3 shows the overall number of positive cultures ac-
cording to the Olympus series of duodenoscopes and demon-
strates that the rate of positive cultures was similar for all se-
ries. There was no difference between the 4 series of duodeno-
scopes in the frequency of positive cultures for any microorgan-
ism (P=0.53). Similarly, there was no difference between the
duodenoscope series in the frequency of positive cultures for
probable pathogens (P=0.13). Also, there was no difference
between the 180 duodenoscopes and the other 3 series com-
bined for the frequency of positive cultures for any microorgan-
ism (P=0.26) or for probable pathogens (P=0.61). 3 of the 5
positive cultures for pathogens from 160 series duodenoscopes
came from 3 different refurbished 160 series instruments.
Of the 13 instruments for which there were 2 positive cul-
tures in succession, the organism was the same genus in both
positive cultures for 8 instruments. We did not further subtype
the organisms or match them for antimicrobial sensitivity to
prove the organisms were identical in the 8 noted cases.
During the study interval, our infection control monitors
identified 17 patients in the hospital with new positive CRE cul-
tures. The number of patients admitted to the hospital with
pre-existing CRE infection is uncertain. There were no duode-
noscope-associated CRE infections identified during the study
period.
Discussion
Protection of patients from iatrogenic injury is of fundamental
and particular importance to the practice of medicine. Recogni-
tion of the potential of ERCP to transmit life-threatening infec-
tions, despite correct performance of all recommended duode-
noscope reprocessing steps, is of great concern to the public, to
endoscopists, to gastroenterology and endoscopy professional
societies, and to regulatory agencies.
Awareness of this issue raises particular concerns at an insti-
tution like ours, where the high volume of ERCPs places a large
number of patients at potential risk of serious infection. We
considered that the high volume of ERCP procedures per-
formed at our institution placed a special burden on us to devel-
op an organized and dedicated response to protect our pa-
tients. The nature of that response is partly dictated by the fea-
sibility of potential protective measures, as it is in any institu-
tion seeking to respond to the threat of duodenoscope trans-
mission of CRE infection. In our institution we elected to evalu-
ate a program of DHLD of duodenoscopes accompanied by cul-
ture and sequestering of a subset of instruments.
This observational report describes the results of our DHLD
protocol. We did not observe CRE infections transmitted by
ERCP during the study period. However, our entire study was
uncontrolled and the expected rate of CRE infections by ERCP
in a similar period in our institution is unknown. Furthermore,
duodenoscope-associated infections are notoriously under-re-
ported, especially in tertiary referral centers with a long-dis-
tance referral base. Contaminated duodenoscopes can also re-
sult in colonization of patients with CREs, and CRE infections
can present weeks to months after the inciting ERCP. Therefore,
the culture results after DHLD are also informative.
The primary result of our study was that DHLD was associat-
ed with low rates of positive culture for both commensals (low
pathogenic potential) and known pathogens (high pathogenic
potential) but did not eliminate positive cultures. We had a
steady flow of positive cultures throughout the study. All 3 pha-
ses of our study were of substantial size and, although we al-
tered the DHLD protocol in an effort to improve the results, all
3 phases had significant rates of positive culture. Therefore, our
primary result is that DHLD does not eliminate positive cultures
from the elevators of duodenoscopes. Our results suggest that
the FDA [20] and the Multisociety guideline [21] should review
their suggestion to utilize DHLD if feasible.
The significance of culturing non-pathogenic organisms
from the elevator mechanism is uncertain, but it seems reason-
able to be concerned that even culture of non-pathogenic or-
ganisms could be a signal pointing toward ineffective cleaning
or disinfection of the elevator mechanism. It remains uncertain
whether the goal of clinical trials or clinical practice should be
the elimination of culture positivity for pathogens or for any mi-
croorganism.
In any case, as we did not culture all of the duodenoscopes, it
seems clear that in some instances we must have performed
▶Table 3 Rates of culture-positive duodenoscopes among the 4 dif-
ferent series of Olympus instruments in our fleet for the 1830 cultures in
the entire study.
Olym-
pus
series
Number
of cul-
tures
taken
Total positive
cultures for any
microorganism,
n (%) [95%CI]
Number of positive
cultures for known
pathogens, n (%)
[95%CI]
180  269 13 (4.8) [2.6–8.1] 0 (0) [0.0 –1.4]
160 1291 87 (6.7) [5.4–8.3] 5 (0.4) [0.1 –0.9]
140  186 10 (5.4) [2.6–9.7] 3 (1.6) [0.3 –4.6]
130   84  7 (8.3) [3.4–16.4] 0 (0) [0.0 –4.3]
CI, confidence interval.
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ERCPs with duodenoscopes that had elevators contaminated
with pathogens. Given this, our preference would be to move
to a policy of universal culture and continue that policy until a
reliable reprocessing method that eliminates pathogens from
the elevator region of duodenoscopes becomes available. How-
ever, we have not yet identified an economically feasible meth-
od to perform universal culture of our duodenoscopes, either
within our clinical laboratory or using an external environmen-
tal laboratory. These approaches might be more feasible for an
ERCP program with a smaller volume of cases or a larger clinical
laboratory.
At this time, having concluded that DHLD cannot effectively
eliminate positive cultures from duodenoscope elevators, we
plan a controlled trial of cold sterilization (peracetic acid) vs.
DHLD accompanied by continuation of the current culture pro-
tocol. ▶Table 1 shows the uncontrolled comparison of positive
culture rates after HLD at Virginia Mason [22] and in the 3 pha-
ses of our study.
After an initial period of observation of DHLD, we intention-
ally changed the precleaning solution to the Medivators Inter-
cept product and then continued the monitoring process. Med-
ivators had presented some unpublished evidence to us that
their Intercept product could reduce biofilm on colonoscopes.
This change was associated with a reduction in the rate of posi-
tive cultures of any microorganism from 9.4% to 4.2%, and of
any known pathogen from 0.8% to 0.3%. However, this reduc-
tion in the rate is a non-randomized observation, and the
change in product coincided roughly in time with the introduc-
tion by Olympus of a new cleaning brush for 160 series duode-
noscopes, and a substantial portion of our fleet is made up of
160 series duodenoscopes. Our results suggest that the foam-
ing agent warrants a controlled assessment of its effect on po-
sitive culture rates. Furthermore, our results may be of use in
formulating hypotheses and sample size estimates for better
controlled prospective trials of cleaning methods and agents.
We also identified that some endoscopes in phase 2 did not
undergo the full second manual disinfection process, though
we believe that the first manual disinfection and both rounds
in the automatic reprocessor occurred in all cases. This event
highlights the importance of monitoring and auditing the HLD
or DHLD process, which remains subject to human error. We
did not see a further drop in the rate of positive cultures in
phase 3, despite retiring 1 duodenoscope with an excessive
number of positive cultures and increasing unannounced spot
audits of the DHLD process (which did not demonstrate any
breaches of the DHLD protocol in phase 3). As noted above,
none of the measures we employed in any of the 3 phases elim-
inated positive cultures from duodenoscope elevators.
When the problem of duodenoscope transmission of CRE
was initially recognized, it appeared the issue might be peculiar
to Olympus 180 series instruments [16]. Our results show clear-
ly that the issue also pertains to 160 series and older instru-
ments. Available evidence indicates that the issue pertains to
duodenoscopes regardless of manufacturer [1–12]. We use
our DHLD protocol for cleaning of endoscopic ultrasound
(EUS) scopes, which also have elevators, though there is cur-
rently uncertainty about the potential of EUS scopes to trans-
mit infection.
Our study strongly supports a policy of systematic culture to
identify individual duodenoscopes that are recurrently culture
positive, which either require special treatment and monitor-
ing, or removal from service. 1 single instrument accounted
for 2 of the 6 positive cultures for pathogens observed during
phases 1 and 2, and had a 25% rate of overall positive cultures.
This observation raises concerns about increased infection risk
in ERCP programs with no biological monitoring of duodeno-
scopes, because 1 or more instruments that are prone to con-
tamination might go unrecognized for prolonged intervals,
thereby potentially causing multiple infections.
We identified 12 instances in which a duodenoscope eleva-
tor was culture positive on 2 successive cultures. In 8 of these
cases the organism was the same genus on both occasions, so
may have represented persistent colonization of the elevator
mechanism. However, we did not further subtype the organ-
isms or match them by antimicrobial sensitivities to determine
with confidence that the organism was the same on both occa-
sions. In at least 4 cases, different organisms on the 2 positive
cultures suggests that environmental contamination might
have contributed to some of the positive cultures in our study.
Certainly, the interpretation of positive cultures for commensal
organisms is subject to error, as these organisms are potentially
introduced by the culture process rather than instrument con-
tamination by exposure to patients.
Our study has a number of limitations. First, we did not ran-
domize duodenoscopes to DHLD vs. single-processing. Instead,
in phase 1, we compared post-DHLD positive culture rates to
the rates after single reprocessing at a different institution. Pri-
marily we used the rates of positive culture from this other in-
stitution to calculate a sample size for the number of cultures
needed in the first portion of this study. However, we did not
consider a comparison between culture rates at our institution
and another institution to be a controlled experiment.
Since we initiated our own study, Brandabur et al. [28] re-
ported the results of single HLD followed by culture of the ele-
vator and/or working channels of duodenoscopes and linear
echoendoscopes at 21 centers. In 4032 surveillance cultures
from 2238 instruments, 8.4% of instruments had positive cul-
tures for any organism and 0.9% had positive cultures for “or-
ganisms of high concern.” The exact rate of positive cultures
from elevators overall in the study was unclear, but in 12 instru-
ments with a positive culture of a pathogen in which the source
of the culture was clear, all 12 instruments had positive cultures
from the elevator. Therefore, the rate of positive culture for pa-
thogens from the elevator after single HLD in the study was
likely higher than we observed after DHLD. Again, however, un-
controlled comparisons of culture positivity rates between dif-
ferent studies is potentially misleading. We therefore consider
our report to be only an observational study describing what
might be expected with DHLD in a prospective experience in a
tertiary center. Given this limitation we certainly cannot ex-
clude that DHLD might reduce the risk of positive cultures and
infection relative to HLD. However, our results clearly indicate
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that DHLD does not eliminate the risk of positive cultures for
pathogenic organisms.
As a second limitation of our study, in the second phase of
the study, we did not randomize instruments to cleaning with
Intercept vs. any other product. The limitations created by this
design have been noted above. In general, the non-randomized
design and the multiple changes to the DHLD protocol made
between and during phases 2 and 3 makes the interpretation
of culture rates between phases challenging. Instead, we be-
lieve the persistence of positive cultures despite multiple
changes in the protocol is the main result of this study.
Third, we cultured only about 30% of the duodenoscopes
treated by DHLD, so we could have missed cultures of serious
pathogens including CREs. However, our sample size of cultures
is large and probably fairly represents the rate of positive cul-
ture that would be observed with universal culturing after
DHLD. There were additional limitations related to our culture
process. For example, we did not culture scopes immediately
after DHLD, which might have reduced our rate of positive cul-
ture, if there was additional drying of the biofilm. Also, we did
not culture instruments after EtO, and EtO may not sterilize in-
struments when biofilm is present.
At this juncture, our goal is to perform a controlled trial of
cold sterilization at our center. Of the options suggested by
the FDA and the Multisociety guideline [20, 21], liquid chemical
sterilization is the remaining option that, given the large vol-
ume of ERCPs at our center, currently seems most feasible for
us to implement with the goal of eliminating positive elevator
cultures. Whether liquid chemical sterilization can eliminate
positive cultures is uncertain [28], but has not been fully eval-
uated.
For the reasons stated earlier, universal culturing [23] is not
feasible at our center and EtO sterilization is neither feasible nor
desirable [22, 24, 25]. HLD remains an important approach for
further investigation and improvement because its cost-effec-
tiveness is superior to other measures [29]. When HLD or
DHLD are used at the current time, our results indicate they
should be accompanied by a degree of microbiological moni-
toring, at least until the design of the elevator is corrected to
allow consistent effective HLD.
We emphasize that feasibility dominated our approach to
disinfection during the study period. Therefore, we did not cul-
ture all of our duodenoscopes after each use because our clini-
cal laboratory found universal culture to be infeasible. We uti-
lized EtO only when instruments were used on patients with
documented infection with a multidrug-resistant organism, or
when cultures from a particular instrument were positive twice
in succession, because we did not have facilities available to
perform EtO on all of our instruments. We suspect that many
endoscopy units would encounter similar feasibility issues with
applying 1 or all of the FDA suggested extra disinfection steps
on a universal basis. We realize that any approach that is not ap-
plied universally to all patients is suboptimal. These challenges
in feasibility underscore the need to develop a novel approach
to disinfection or sterilization of duodenoscopes that is both
universally effective and widely feasible.
In summary, DHLD did not eliminate the risk of transmission
of serious infection by duodenoscopes. DHLD, although sug-
gested by both the FDA and the Multisociety guideline as a po-
tential extended reprocessing step for units with the feasibility
to conduct it, is not the answer to eliminating positive cultures
from duodenoscopes. Our results indicate the need for further
modifications of HLD and/or duodenoscope design to achieve
eradication of organisms from the elevators of duodenoscopes.
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